Marker Predicts Outcomes in mCRPC Treated With AR-Targeted Therapy

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Findings from the COMET trial support the potential safety and acceptability of active monitoring among patients with ductal carcinoma in situ.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.